1-3 of 3
Gary D. Means
Close
Sort by
Journal Articles

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

Jing Yang, PhD, Jan L. Hillson, MD, Kristi L. Manjarrez, Jennifer R. Wiley, DRSc, Gary D. Means, PhD, Stacey R. Dillon, PhD, Stanford L. Peng, MD,PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 372.
https://doi.org/10.1182/blood-2019-126034
Published: 2019
Journal Articles

CD33 SNP Genotype and Splice Variation Are Associated with CD33 Cell Surface Expression and SGN-CD33A Pharmacokinetics

Katherine Tarlock, MD, Zixing Wang, Rory Rohm, Travis Biechele, Rhonda E. Ries, MA, Tiffany Hylkema, BS, Jatinder K Lamba, PhD, Gary D Means, PhD, Robert Thurman, Bill Arthur, Soheil Meshinchi, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3942.
https://doi.org/10.1182/blood-2018-99-113932
Published: 2018
Journal Articles

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington, Justine Dell’Aringa, Kathryn J. Newhall, Gary D. Means, Angus M. Sinclair, Roman Kischel, Stanley R. Frankel, Roland B. Walter
Journal: Blood
Blood (2014) 123 (4): 554–561.
https://doi.org/10.1182/blood-2013-09-527044
Published: 2014
Includes: Supplemental data